11don MSN
Rallybio shares successful early-stage results for rare disease drug; new trial set for late 2026
Rallybio Corporation RLYB on Tuesday shared results from its Phase 1 confirmatory pharmacokinetic/pharmacodynamic (PK/PD) ...
It was called ‘complement’ because it aided the antibacterial activity of antibodies. However, it is now known that the complement system can be activated early in an infection without the presence of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results